💥Join UPSC 2027,2028 Mentorship (August Batch) + XFactor Notes & Microthemes PDF
Talk to Mentor

Civilsdaily

Login

Subject: Biotech and Medical Sciences

  • WHO Issues Global Guidelines on GLP-1 Drugs for Obesity 

    Why in the News?

    The World Health Organization (WHO) has released its first global guidelines (Dec 1, 2025) supporting the use of GLP-1 (Glucagon-Like Peptide-1) drugs as long-term treatment for obesity in adults, alongside diet and exercise.
     These guidelines emphasise equitable access, affordability, and caution about long-term safety.

    What are GLP-1 Drugs?

    • GLP-1 = Glucagon-Like Peptide-1 receptor agonists
    • Originally developed for type 2 diabetes
    • Now widely used for medically supervised weight loss
    • Examples: Semaglutide, Tirzepatide, Liraglutide
    • Mechanism:
      • Reduce appetite
      • Slow gastric emptying
      • Improve insulin sensitivity

    Key WHO Recommendations

    Conditional approval for adults

    • GLP-1 drugs may be used for long-term obesity management
    • Excluded: pregnant women
    • Reason for “conditional” status:
      • Limited long-term efficacy & safety data
      • Uncertainty about outcomes after discontinuation
      • High cost and global inequity in access

    Must be combined with lifestyle interventions

    • Balanced diet + regular physical activity remain essential
    • Drugs cannot replace behavioural changes

     Equity and affordability

    • WHO urges:
      • Generics development
      • Insurance coverage
      • Lower pricing
    • Obesity’s global economic cost projected to reach $3 trillion by 2030
    A company marketing food product advertises that its items do not contain trans-fats. What does this campaign signify to the customers? (2011)

    1. The food products are not made out of hydrogenated oils. 

    2. The food products are not made out of animal fats/oils. 

    3. The oils used are not likely to damage the cardiovascular health of the consumers. 

    (a) 1 only (c) 1 and 3 only (b) 2 and 3 only (d) 1, 2 and 3

  • [2nd December 2025] The Hindu OpED: The new action plan on AMR needs a shot in the arm

    PYQ Relevance

    [UPSC 2014] Can overuse and free availability of antibiotics without Doctor’s prescription, be contributors to the emergence of drug-resistant diseases in India? What are the available mechanisms for monitoring and control? Critically discuss the various issues involved.

    Linkage: This PYQ directly mirrors the article’s focus on antibiotic misuse, OTC access, and weak regulatory control driving AMR. It lets you use NAP-AMR 2.0 to show gaps in surveillance, stewardship, and One Health governance, exactly what the exam tests.

    Mentor’s Comment

    AMR is now a major threat to India’s health, food systems, and environment. Resistance has moved beyond hospitals into water, soil, and livestock. NAP-AMR 2.0 is timely and shows a stronger, more accountable approach. This analysis helps you clearly understand what worked, what failed, and what must change.It also builds GS2 and GS3 depth through governance, science, environment, and One Health linkages.

    Introduction

    India has released its National Action Plan on Antimicrobial Resistance (NAP-AMR 2.0) for 2025-29, signalling a renewed commitment to containing AMR, a challenge that affects human health, livestock, agriculture, the environment, and food systems. Unlike the first plan (2017), which saw uneven adoption across States, the second plan attempts structural reform through higher accountability, stronger surveillance, private-sector engagement, multi-departmental integration and One Health alignment.

    Why in the news?

    The launch of NAP-AMR 2.0 marks a significant turning point because AMR has now expanded beyond hospitals into soil, water, livestock, markets and food systems, making it a full-spectrum health and environmental challenge. 

    How did the first NAP-AMR evolve and where did it fall short?

    1. Significant early progress: Brought AMR into national consciousness, encouraged multi-sectoral participation, improved laboratory networks, and strengthened stewardship.
    2. One Health recognition: Placed AMR within the interface of human health, animals and environment.
    3. State-level stagnation: Most States undertook only individual activities; only a few (Kerala, MP, Delhi, AP, Gujarat, Sikkim, Punjab) created formal AMR action plans.
    4. Weak institutional execution: Multisectoral One Health structures were missing in most States.
    5. Uneven governance: Human health, veterinary systems, pharmaceuticals and waste management lie under different jurisdictions, causing weak coordination.
    6. Monitoring deficiencies: Surveillance, regulatory oversight, environmental contamination monitoring and antibiotic stewardship remained fragmented.

    What makes NAP-AMR 2.0 more mature and implementation-focused?

    1. Shift to national priorities: Moves beyond intent; outlines clear responsibilities across levels of governance.
    2. Private sector engagement: Recognises that a major share of India’s health care and veterinary services is provided privately.
    3. Scientific strategy: Emphasises innovation, rapid diagnostics, alternatives to antibiotics, and improved environmental monitoring.
    4. One Health deepening: Stronger coordination across food safety, waste management, agriculture, environment and human/animal health.

    What new governance mechanisms does the NAP-AMR 2.0 introduce?

    1. Higher accountability: Greater role for national supervision through a dedicated Coordination and Monitoring Committee.
    2. State-level innovation: Recommends every State establish a One Health inter-ministerial AMR committee, along with State AMR cells.
    3. Integrated reporting framework: Aligns State reporting with national structures for uniform monitoring.
    4. Technical backbone: Calls for a national follow-up mechanism and a multi-departmental coordinating structure.

    Where do administrative and operational gaps persist?

    1. Funding limitations: NITI Aayog’s earlier financial grant-based system did not generate adequate incentives.
    2. Weak incentive design: No system for rewarding State performance or penalising poor progress.
    3. Fragmented responsibility: Human health, veterinary systems, agriculture, pharmaceuticals and waste sectors work under separate ministries and State departments.
    4. Lack of real-time accountability: No statutory notification requiring States to inform the Centre of AMR progress.
    5. Dependence on central push: States often wait for Union-level initiatives rather than proactively building AMR infrastructure.

    What financial and institutional reforms does the article highlight as essential?

    1. Mandatory funding channels: Conditional grants through the National Health Mission (NHM) for surveillance and laboratory systems.
    2. Administrative energy: Once funding becomes compulsory, States respond faster.
    3. Scientific backbone: Need for a sustainable, long-term national centre for AMR control and accountability.
    4. International relevance: Without a Centre-backed national AMR programme, India cannot engage in meaningful global AMR governance.

    Conclusion

    The NAP-AMR 2.0 offers an opportunity to anchor India’s AMR response on a stronger scientific and institutional foundation. But success will require coordinated State participation, financial backing, and accountable governance, not just policy intention. A central AMR Centre, integrated surveillance, and enforceable incentives could finally convert national plans into ground-level action across health systems, veterinary services, agriculture, food safety and environmental management.

  • Aloe vera Compounds as Potential Alzheimer’s Inhibitors  

    Why in the news?

    A new study (Current Pharmaceutical Analysis, 2025) suggests that common plant molecules from Aloe vera—especially Beta sitosterol—may inhibit key enzymes associated with Alzheimer’s disease (AD). Findings are based entirely on in silico (computer simulation) techniques.

    What is Computer Simulation (In Silico Research)?

    • Computer simulation, often called in silico research, refers to the use of computational tools and algorithms to model biological, chemical, or physical processes.
    • It allows scientists to predict molecular interactions, drug behavior, and biological outcomes without physical experiments.

    Alzheimer’s Disease (AD) 

    • Most common form of dementia.
    • Characterised by:
      • Memory loss
      • Cognitive decline
      • Accumulation of beta-amyloid plaques and tau tangles
      • Loss of acetylcholine, a neurotransmitter linked to learning and memory.
    • Enzymes involved in acetylcholine breakdown:
      • Acetylcholinesterase (AChE)
      • Butyrylcholinesterase (BChE)
    • Current drugs (e.g., donepezil, rivastigmine) work by inhibiting these enzymes but do not stop disease progression.

    Why Aloe vera?

    • Used for 3000+ years in traditional medicine.
    • Contains bioactive compounds such as Beta sitosterol, Succinic acid, polysaccharides, and phenolics.

    Major Findings

    • Beta sitosterol showed strong binding affinity to both enzymes:
      • AChE: −8.6 kcal/mol
      • BChE: −8.7 kcal/mol
    • The binding strength is higher than that of other screened compounds like Succinic acid.
    • ADMET results suggest:
      • Good absorption
      • Low toxicity
      • Favourable pharmacokinetic profile
    Which one of the following is the context in which the term “qubit” is mentioned? (2022)

    (a) Cloud Services 

    (b) Quantum Computing 

    (c) Visible Light Communication Technologies 

    (d) Wireless Communication Technologies

    This PYQ is chosen because it tests a fundamental concept related to the cutting edge of computational power and modelling, which is the operational domain of computer simulation.

  • Sleep Apnea & Parkinson’s Disease 

    Why in the News?

    • A new study published in JAMA Neurology (Nov 24, 2025) found that untreated Obstructive Sleep Apnea (OSA) can nearly double the risk of developing Parkinson’s disease.
    • The study analysed 11 million+ U.S. military veterans’ medical records (1999–2022).
    • Use of CPAP (Continuous Positive Airway Pressure) significantly reduces the elevated risk, making sleep quality a potential neuroprotective factor.

    Key Findings

    • Untreated OSA → ~2× higher likelihood of developing Parkinson’s.
    • CPAP therapy helps maintain oxygen levels → reduces neurodegeneration risk.
    • Repeated oxygen drops during sleep may lead to long-term neuronal stress.
    • Parkinson’s disease risk increases naturally with age, especially >60 years, but untreated OSA further elevates vulnerability.

    About Parkinson’s Disease 

    • A progressive neurodegenerative disorder affecting movement.
    • Caused by loss of dopaminergic neurons in the substantia nigra.
    • Symptoms: tremors, rigidity, bradykinesia, cognitive decline (late stages).
    • No cure; treatments focus on symptom management.

    Prelims Pointers

    • New association identified: OSA ↔ Parkinson’s disease risk.
    • Published in JAMA Neurology.
    • Largest dataset used for this linkage: 11 million veterans.
    • CPAP is not just a sleep device—it may offer neuroprotection.
    • Chronic intermittent hypoxia implicated in neurodegeneration.
    Excessive release of the pollutant carbon monoxide (CO) into the air may produce a condition in which oxygen supply in the human body decreases. What causes this condition? (2010)

    (a) When inhaled into the human body CO is converted into CO2

    (b) The inhaled CO has much higher affinity for haemoglobin as compared to oxygen

    (c) The inhaled CO destroys the chemical structure of haemoglobin

    (d) The inhaled CO adversely affects the respiratory centre in the brain

    This PYQ is chosen because the core pathological connection linking Sleep Apnea and Parkinson’s disease is the concept of chronic oxygen deprivation (Hypoxia) and its neurodegenerative impact.

  • Moss Spores Survive Months in Space

    Why in the news?

    A recent study published in iScience revealed that moss spores (Physcomitrium patens) survived nine months outside the International Space Station (ISS), enduring vacuum, cosmic radiation, microgravity, and temperature extremes. Over 80% of the spores survived and successfully germinated on return to Earth. Scientists estimate moss could survive up to 15 years in space.

    Key Findings of the Study

    • 20,000 moss spores were placed outside the ISS in March 2022.
    • Exposed to: Vacuum, Cosmic radiation, Microgravity and Extreme temperatures
    • After 283 days, the spores were retrieved.
    • Results: 80% survived
      • Among survivors, 89% germinated successfully
      • Chlorophyll levels normal except a 20% drop in chlorophyll a, but not harmful
    • Survival attributed to multiple spore wall layers offering passive protection.

    About the Species

    • Species: Physcomitrium patens
    • Model organism for plant evolutionary studies
    • Mosses are one of the earliest land plants
    • Already known for surviving:
      • Antarctica
      • Volcanic fields
      • Deserts

    Why Moss Survived – Scientific Insight

    • Multiple thick-walled layers → physical shielding
    • Ability to remain in dormant state
    • Natural mechanisms to handle:
      • Radiation
      • Desiccation
      • Freezing and thawing cycles

    Why Is This Significant?

    • Implications for Space Exploration: 
        • Ability to survive harsh space environments → potential role in: Oxygen generation, Humidity control, Soil formation on Moon/Mars.
        • Supports concepts of bioregenerative life-support systems
        • It could be used in terraforming experiments on other celestial bodies

    • Astrobiology

        • Supports the idea that primitive plant life could survive interplanetary transport.
        • Relevant to panspermia hypothesis (life spreading across planets via spores).

    • Long-term Human Habitats

      • Moss can grow with minimal resources
      • Can contribute to:
        • Closed-loop ecosystems
        • Sustainable habitats
        • Psychological well-being in isolated environments (greenery)
    Consider the following statements: (2023)

    1. Some microorganisms can grow in environments with temperature above the boiling point of water. 

    2. Some microorganisms can grow in environments with temperature below the freezing point of water. 

    3. Some microorganisms can grow in highly acidic environment with a pH below 3. 

    How many of the above statements are correct? 

    (a) Only one (b) Only two (c) All three (d) None

  • Overcoming resistance: On the National Action Plan on Antimicrobial Resistance (2025–29)

    Introduction

    The Government has introduced the second iteration of the National Action Plan on Antimicrobial Resistance (NAP-AMR) in response to escalating resistance to antibiotics across sectors. While version 1 generated marginal gains and placed AMR on India’s health agenda, its sluggish implementation led to persistent misuse of antibiotics, weak state collaboration, and rising resistance. New evidence, including the 2023 WHO Global Antibiotic Resistance Surveillance report, confirms the urgency for renewed stewardship and a strengthened One Health strategy.

    Why in the News?

     India has launched Version 2 of the National Action Plan on AMR amid alarming data that in 2023, one in three bacterial infections in India showed resistance to commonly used antibiotics, against one in six globally. The spike comes despite NAP-AMR (2017–21), revealing that implementation, not intent, is the major roadblock. The new plan is a crucial attempt to arrest a humongous health, veterinary and environmental crisis before last-line antibiotics become fully ineffective.

    Why did Version 1 of NAP-AMR fall short?

    1. Sluggish implementation: Raised the profile of AMR nationally but failed to translate into coordinated ground-level action.
    2. Weak state participation: Only a few states formulated policies; Kerala alone implemented effectively, registering a slight drop in AMR levels.
    3. Narrow ecosystem focus: Neglect of veterinary, environment, agriculture and aquaculture vectors.
    4. Enforcement gaps: Despite a ban on Colistin as a growth promoter in the husbandry sector, misuse continued in varying degrees.

    How serious is AMR in India today?

    1. High disease burden: High infectious disease load increases antibiotic exposure and accelerates resistance.
    2. Overuse and misuse: Indiscriminate use in healthcare and self-medication remain widespread.
    3. Critical pathogens advancing: E. coli and Klebsiella pneumoniae show high resistance to critical antibiotics, rendering last-line drugs ineffective.

    Why has AMR become a multi-sectoral challenge?

    1. Agriculture & husbandry: Growth promoters and preventive antibiotic usage fuel microbial resistance.
    2. Veterinary medicine: Improper prescription and uncontrolled access to antibiotics.
    3. Soil & water contamination: Antibiotic residues affect ecosystems and re-enter human food chains.
    4. Aquaculture & food processing: Residues facilitate community-level resistance.

    Why is One Health no longer optional?

    1. Integrates human, animal and environmental health to handle widespread resistance emerging across the food chain and biosphere.
    2. Breaks inter-sectoral silos to ensure synchronised surveillance and regulation.
    3. Guides community-level resistance mitigation, not just tertiary hospitals.

    What must Version 2 achieve to succeed?

    1. Strong antibiotics stewardship programmes across community and hospital settings.
    2. Reliable nationwide surveillance network beyond pandemic-led laboratory expansion.
    3. State partnership and compliance mechanisms rather than voluntary policy uptake.
    4. Accountability measures for misuse in human healthcare, veterinary practice and agriculture.

    Conclusion

    India stands at a critical point where policy intent must translate into enforceable implementation. The success of NAP-AMR (Version 2) depends on strong stewardship, inter-state coordination, and an uncompromising One Health approach. Without systemic commitment, antibiotic resistance risks becoming the defining public health disaster of the decade.

    Value Addition

    What is AMR? 

    • Antimicrobial Resistance (AMR) refers to a biological phenomenon in which microorganisms such as bacteria, viruses, fungi, and parasites evolve to resist the action of antimicrobial drugs. As a result, standard treatments become ineffective, infections persist, and the risk of spread, severe illness, and mortality increases.

    India AMR data cue:

    • WHO Global Antibiotic Resistance Surveillance Report (2023): 1 in 3 bacterial infections in India resistant to commonly used antibiotics, compared to 1 in 6 globally.

    Kerala as a Model State 

    • Kerala is often cited as the only state that implemented its state-level action plan on AMR effectively enough to show measurable impact.
    • Key success factors:
      • Strong state-led antibiotic stewardship programme
      • Mandatory prescription audits and regulation of over-the-counter sales
      • Hospital-level AMR surveillance linked to community-level action
      • Training of medical and veterinary practitioners
      • Public awareness + behavioural campaigns

    PYQ Relevance

    [UPSC 2014] Can overuse and free availability of antibiotics without Doctor’s prescription, be contributors to the emergence of drug-resistant diseases in India? What are the available mechanisms for monitoring and control? Critically discuss the various issues involved.

    Linkage: This question is directly relevant as India faces one of the world’s highest AMR burdens driven by misuse and over-the-counter sale of antibiotics. It links to National Action Plan on AMR (Version 2), antibiotic stewardship, surveillance gaps, and public health governance.

  • Pharmacogenomics: reading genes to tailor prescriptions for individuals

    Why In The News?

    Pharmacogenomics is transforming healthcare by showing how genetic differences affect individual drug responses. This breakthrough emerging technology is replacing traditional “start low, go slow” trial-and-error prescribing with personalised, precision-based treatment that improves effectiveness and reduces harmful reactions.

    1) What is Pharmacogenomics?

    • Definition & Purpose: Studies how genetic variations affect drug response, determining whether a drug will be effective, ineffective, or harmful.
    • Role of Enzymes: Differences in drug-metabolising enzymes, especially the CYP450 family, impact the metabolism of ~75% of common drugs.
    • Metaboliser Phenotypes:
      • Poor Metaboliser: Low enzyme activity → toxic drug buildup at standard doses.
      • Ultrarapid Metaboliser: High enzyme activity → reduced therapeutic benefit.
    • Widespread Variants: About 90% of people carry at least one actionable pharmacogenetic variant.
    • Clinical Impact: Genetic factors significantly contribute to adverse drug reactions (ADRs), a major cause of hospitalisation and death in developed nations.

    2) Understanding the Problem in Traditional Prescribing:

    • Traditional Approach – “Start Low, Go Slow”: Reflects the challenge that the same drug and dose can heal one patient but harm another.
    • Population-Based Prescribing: For decades, medications were prescribed based on population averages, leading to trial-and-error treatment.
    • Shift Toward Precision: Pharmacogenomics is transforming this approach by showing how genes influence drug response, moving from guesswork to precision.

    3) Real-World Applications:

    • Warfarin Dosing:
      • Variants in CYP2C9 and VKORC1 explain ~50% of dose variation.
      • Genetic-guided dosing reduces bleeding risk and allows faster achievement of therapeutic levels.
    • Clopidogrel Activation:
      • Requires CYP2C19 for activation.
      • CYP2C19*2 variants (25–30%) → poor activation → higher risk of stent thrombosis.
      • CPIC 2022 guidelines recommend alternatives for poor metabolisers.
    • Psychiatry:
      • Many antidepressants/antipsychotics rely on CYP2D6 and CYP2C19.
      • Testing reduces side effects, improves symptom control, and lowers costs.
    • Oncology: Rapid progress in using genetic markers to personalise cancer treatment.

    4) Economic Considerations:

    • Cost Reduction: Genetic test prices have dropped from thousands to $200-500 for large panels.
    • Cost–Effectiveness:
      • Testing prevents adverse events and improves outcomes, proving cost-effective, especially in chronic diseases.
    • Evaluation Framework: Value depends on factors such as severity of side-effects, frequency of variants, availability of alternative drugs, and variability in clinical settings.
    • Preventive Value: Avoiding even one serious ADR can offset the cost of testing many patients.

    5) Implementation Challenges:

    • Provider Knowledge Gaps: Most clinicians lack training in pharmacogenomics, making interpretation difficult.
    • Infrastructure Limitations: Electronic health records often lack tools to integrate genetic data into prescribing workflows.
    • Reimbursement Issues: Insurance coverage remains inconsistent, creating hesitation.
    • Regulatory Complexity:
      • Over 100 FDA drug labels include pharmacogenomic information.
      • Some provide actionable guidance; others are only informative.
    • Cultural & Institutional Barriers: Requires changes in clinical culture, administrative support, and trained champions to lead adoption.

    6) The Path Forward:

    • Pre-emptive Testing: Future lies in obtaining genetic profiles before medications are needed, enabling lifelong personalised prescribing.
    • Fundamental Shift: Moves healthcare from population-based to individualised, from reactive to proactive, and from trial-and-error to precision medication.
    • Genomic Insight: Our genes guide our prescriptions-pharmacogenomics teaches us how to read this biological roadmap.
    [UPSC 2023] ‘Aerial metagenomics’ best refers to which one of the following situations?

    Options: (a) Collecting DNA samples from air in a habitat at one go*

    (b) Understanding the genetic makeup of avian species of a habitat

    (c) Using air-borne devices to collect blood samples from moving animals

    (d) Sending drones to inaccessible areas to collect plant and animal samples from land surfaces and water bodies

  • What are UNESCO new guidelines for the use of neurotechnology

    Introduction

    Neurotechnology includes devices and procedures that access, assess, or act upon neural systems. Earlier limited to health care, it now merges neuroscience, AI, computing, and engineering to improve or manipulate brain function. Rapid investments, private-sector involvement, and research innovations, such as brain implants enabling paralysed patients to speak, have increased both possibilities and ethical risks. UNESCO’s new standard attempts to balance innovation and human rights, defining responsibilities for governments, researchers, and companies.

    Why in the News? 

    UNESCO has issued the world’s first global normative framework on the ethics of neurotechnology, marking a major shift in global governance of brain-data systems. This is historic because neurotechnology, once confined to medicine, now expands into marketing, political persuasion, employment screening, insurance, and behaviour profiling. With misuse risks escalating and national laws lagging behind, UNESCO’s framework seeks to protect mental privacy, cognitive liberty, and brain-derived data in an era where neurodata can be exploited commercially or politically.

    How does the article define neurotechnology?

    1. Devices/Procedures: Used to access, assess, and act on neural systems including the brain.
    2. Neurodata: Brain-derived data that can reveal intentions, emotions, or mental states, posing risks of exploitation.
    3. Dual-use potential: While used for medical enhancement or disability support, the same can be misused for persuasion, surveillance, or profiling.

    Why is neurotechnology expanding so rapidly?

    1. Investment surge: According to a UNESCO study (2023), neurotechnology investment reached $8.6 billion, with private investment growing from $7.3 billion by 2020.
    2. Big tech involvement: Projects like US BRAIN Initiative, Elon Musk’s Neuralink accelerating market adoption.
    3. Medical promise: Supports mental health, paralysis recovery, chronic illness treatment, and palliative care.
    4. Commercial incentives: Insurance sector, HR screening, political messaging all exploring neurodata applications.

    What are the key challenges highlighted?

    1. Mental privacy threats: Neurodata gives deep access to personal thoughts; existing legal standards insufficient.
    2. Political misuse: Brain signals used to influence voters or detect political leanings.
    3. Employment misuse: Screening employees for suitability, stress tolerance, or hidden traits.
    4. Commercial exploitation: Recruiting applicants based on subconscious brain responses to marketing stimuli.
    5. Human rights concerns: Risk of discrimination, autonomy loss, and manipulation.

    What does UNESCO’s new framework propose?

    1. Human rights foundation: Anchors mental privacy, liberty, dignity.
    2. Responsible innovation: Based on OECD principles, responsibility, inclusion, sustainability.
    3. Four-pronged strategy:
      1. Scope definition of neurotechnology and neurodata.
      2. Identification of ethical principles for countries.
      3. Recommendations focusing on health, education, and vulnerable groups.
      4. Governance considerations for safety and equity.
    4. Intellectual property balance: Calls attention to potential conflicts between innovation and human rights when brain data becomes privatised.
    5. Open science model: Encourages free sharing of discoveries for societal benefit.
    6. Inclusive innovation: Participation of public, stakeholders, scientists, vulnerable communities.

    What are the implications for governance and public policy?

    1. AI-Neuro convergence: Need for regulations preventing manipulation or exploitation of neural activity.
    2. Global governance: Calls for adoption by states to standardize mental privacy protections.
    3. Sectoral impact: Health, education, military, and employment policies require safeguards.
    4. IP reform: Recommends new licensing structures to prevent monopolisation of brain-interfacing technologies.
    5. R&D ethics: Researchers to involve the public and align innovations with societal needs, not corporate priorities.

    Conclusion

    UNESCO’s guidelines mark a foundational step in governing an emerging field where technological capacity has outpaced ethics. By protecting mental privacy and anchoring innovation within a human-rights framework, the guidelines seek to ensure neurotechnology remains a tool for empowerment rather than manipulation. For India and other countries, the challenge lies in integrating these recommendations into national law and ensuring safe, inclusive, and responsible neuro-innovation.

    PYQ Relevance

    [UPSC 2023] How can Artificial Intelligence (AI) help clinical diagnosis? Do you perceive any threat to privacy of the individual in the use of AI in healthcare?

    Linkage: This directly links to the PYQ on AI in clinical diagnosis because neurotechnology goes even deeper, AI can now read and interpret brain signals, making privacy risks far sharper than ordinary medical data. The same issue fits under Ethics too, since it raises questions about autonomy, consent, dignity, and the basic right to mental privacy.

  • India’s Emerging Frontier in Precision Biotherapeutics 

    Why in the News?

    India’s growing burden of non-communicable diseases and its vast genetic diversity make precision biotherapeutics and targeted therapies a strategic medical priority.

    About Precision Biotherapeutics:

    • Concept: Precision biotherapeutics are targeted medical treatments – gene therapies, biologics, mRNA drugs, engineered antibodies – designed according to a patient’s genetic, molecular, or cellular profile.
    • Scientific Basis: Integrates genomics, proteomics, cell engineering, computational biology, and AI to correct disease at its root rather than treating symptoms.
    • Genetic Targeting: Uses genomic and proteomic profiling to identify mutations and dysfunctional biological pathways.
    • Gene Editing: Employs CRISPR and related tools to repair faulty genes, including those causing haemoglobin disorders.
    • Nucleic-Acid Therapies: Uses mRNA, siRNA, and DNA-based platforms that instruct cells to produce or suppress specific proteins.
    • Biologics & Antibodies: Develops monoclonal antibodies and targeted biologics for cancer, autoimmune diseases, and metabolic disorders.
    • AI Integration: AI systems accelerate drug discovery, target prediction, and personalised therapy development.

    Why India needs precision Biotherapeutics?

    • High Disease Burden: Non-communicable diseases cause ~65 percent of deaths; standard therapies ignore India’s biological diversity.
    • Genetic Variation: Indian populations show wide genetic diversity, making foreign-developed drugs less effective in many groups.
    • National Genome Projects: Initiatives such as GenomeIndia and IndiGen create datasets enabling population-specific therapies.
    • Healthcare Shift: Enables movement from reactive treatment to predictive, preventive, and personalised care.

    Where does India stand today?

    • Policy Recognition: Identified as a major pillar in the BioE³ Policy of DBT and BIRAC.
    • Research Strength: Organisations like IGIB, NIBMG, THSTI are mapping Indian genetic variations.
    • Industry Growth: Rapid expansion in biosimilars, immunotherapies, precision oncology, gene therapy.
    • Key Players: Biocon Biologics, Dr Reddy’s, Zydus LifeSciences, Immuneel Therapeutics, ImmunoACT, 4baseCare, Akrivia Biosciences, Bugworks, miBiome Therapeutics.
    • Challenges: Nascent regulation limited advanced biomanufacturing, high therapy costs.

    Global Progress and Benchmarks:

    • Regulatory Leaders: US and EU have clear approval pathways for cell and gene therapies.
    • Breakthroughs: Approvals like Zolgensma (SMA) and Casgevy (first CRISPR therapy).
    • Asia’s Momentum: China hosts 800+ active trials; Japan and South Korea use fast-track frameworks for regenerative medicine.

    Opportunities:

    • Disease Impact: Precision therapies improve outcomes for genetic, metabolic, rare, and cancer conditions, reducing long-term costs.
    • Market Potential: Global precision medicine market projected to exceed 22 billion USD by 2027.
    • India’s Edge: Strong IT ecosystem, data science capacity, cost-efficient manufacturing, and large clinical trial base.

    Risks:

    • Genomic Privacy: Sensitive data risks misuse without strict laws and consent rules.
    • Cost Barriers: High treatment costs may deepen health inequity.
    • R&D Gaps: Low domestic R&D investment can create dependence on foreign technologies.

    Way Forward:

    • Regulation: Establish a dedicated CDSCO pathway for cell and gene therapies.
    • Data Protection: Enact a biobanking and genomic data law ensuring privacy and research access.
    • Affordability: Integrate precision therapies into public insurance and health schemes.
    • Ethics & Governance: Create national standards on consent, fairness, and data use.
    • Manufacturing: Expand domestic biologics and gene therapy infrastructure to reduce import reliance.
    [UPSC 2024] In which of the following are hydrogels used?
    1. Controlled drug delivery in patients
    2. Mobile air-conditioning systems
    3. Preparation of industrial lubricants
    Select the correct answer using the code given below:
    Options: (a) 1 only (b) 1 and 2 only (c) 2 and 3 only (d) 1, 2 and 3*

     

  • Holding up GLASS to India: securing stewardship to tackle AMR

    INTRODUCTION

    AMR in India is now labelled a “serious and escalating threat”, with the latest WHO GLASS report (2025) confirming extraordinarily high resistance levels across commonly used antibiotics. Nearly one in five severe infections in India mirrored or exceeded South and East Asian trends, and one in six confirmed infections was resistant. India’s high infectious disease burden, misuse of antibiotics, weak surveillance, and gaps in healthcare infrastructure continue to aggravate the problem. The article highlights incomplete data, insufficient funding, fragmented stewardship, and the urgent need for rational antibiotic use, surveillance strengthening, and affordable new-generation antibiotics.

    WHY IN THE NEWS? 

    India features prominently in the WHO’s October 2025 GLASS report, which confirms that the country now records some of the highest antibiotic resistance rates globally, particularly for gram-negative pathogens. For the first time, GLASS shows significant data gaps, reflected in India uploading surveillance results from only tertiary hospitals, leaving rural and peripheral areas undocumented. The report highlights a sharp contrast with global progress, exposing India’s limited surveillance expansion, weak stewardship, and slow adoption of newer effective antibiotics, despite AMR being among the country’s gravest public-health threats.

    Understanding the Scale of AMR in India

    1. High Resistance Rates: India shows disproportionately high resistance to commonly used antibiotics, especially in infections caused by E. coli, Klebsiella pneumoniae, Staphylococcus aureus, and pathogens causing sepsis in ICUs.
    2. Escalating Threat Category: WHO labels AMR in India as a “serious and escalating threat,” placing India among the highest global burden countries.
    3. Gram-Negative Pathogens: Severe risks emanate from resistance trends in gram-negative bacteria which limit treatment options in hospitals.
    4. Community-Hospital Gap: Surveillance primarily reflects tertiary hospital data, leaving a large rural and primary-care void, producing incomplete national estimates.

    Why Current Surveillance is Insufficient

    1. Incomplete Data Representation: GLASS data reflects only a segment of India’s population; peripheral, rural, and primary-care levels remain unrepresented, leading to erroneous conclusions.
    2. Fragmented Networks: Laboratories under NCDC’s AMR and AMRRSN networks provide data, but coverage is inadequate for a country of India’s scale.
    3. Operational Challenges: Shortage of trained microbiologists, inconsistent reporting, and infrastructure deficits weaken surveillance reliability.
    4. Underestimation of Burden: Without wider surveillance, actual AMR spread across different geographies or demographic groups remains unknown.

    Kerala’s State-Led Model of AMR Management

    1. State Action Plan Success: Kerala’s progress stems from early adoption of the State Action Plan aligned with India’s National Action Plan (NAP-AMR).
    2. Whole-of-System Approach: Kerala integrates veterinary, human health, and environmental data, demonstrating One Health operationalisation.
    3. Institutional Leadership: Dedicated stewardship committees and infection-control protocols ensure sustained monitoring and policy continuity.

    Antibiotic Stewardship and Public Awareness Challenges

    1. Unregulated Antibiotic Use: Easy over-the-counter access, self-medication, and incomplete courses contribute to rising resistance.
    2. Hospital Overuse: Lack of stewardship committees and infection-control practices deepen resistance in ICUs and emergency departments.
    3. Limited Community Awareness: Behavioural change campaigns remain inadequate, leading to misconceptions about antibiotic effectiveness.
    4. Inappropriate Prescriptions: Physicians often prescribe broad-spectrum antibiotics without culture sensitivity results due to delays or lack of labs.

    Innovation, R&D Pipelines and the Crisis of New Antibiotics

    1. Weak Domestic Innovation: Only 2 of the 32 antibiotics under global development meet WHO innovation criteria.
    2. Positive Trend: India’s CDSCO approved two new antibiotic candidates recently, while six others received global approval.
    3. Global Gap: Out of 97 candidates in preclinical pipelines (2022), few target WHO’s priority pathogens.
    4. High Barriers: Costly R&D, limited incentives, and delayed regulatory approvals weaken India’s innovation environment.

    Global and National Funding Gaps

    1. Insufficient Domestic Funding: India’s AMR response suffers from limited financial allocations, affecting surveillance expansion and lab capacity building.
    2. Gaps in Multilateral Support: Despite WHO’s Global AMR Challenge, LMICs like India lack sustained funding for new antibiotics and diagnostics.
    3. Need for Collaborative Platforms: Strengthened partnerships with bodies like the AMR Industry Alliance and CARB-X can accelerate innovation pipelines.

    Why Solutions Must Prioritise Stewardship, Surveillance, and Affordability

    1. Urgency of Behaviour Change: Stewardship requires both medical and community engagement to reduce irresponsible antibiotic use.
    2. Strengthening Peripheral Health Systems: Decentralised surveillance networks are essential to capture India’s actual AMR burden.
    3. Making New Antibiotics Accessible: India must prioritise affordability and availability given rising MDR (multi-drug resistant) infections in LMICs.
    4. Integrating One Health: Coordinated animal-human-environmental monitoring is indispensable for durable AMR containment.

    CONCLUSION

    India stands at a critical juncture where AMR has outpaced existing stewardship, surveillance, and innovation capabilities. The GLASS 2025 report acts as a mirror reflecting the country’s systemic gaps, from incomplete data and misuse of antibiotics to insufficient funding and slow R&D advancement. A robust national response must integrate strong stewardship, affordable innovation, decentralised surveillance, and a One Health framework to prevent AMR from becoming an unmanageable public-health catastrophe.

    PYQ Relevance

    [UPSC 2014] Can overuse and free availability of antibiotics without Doctor’s prescription be contributors to the emergence of drug-resistant diseases in India? What are the available mechanisms for monitoring and control? Critically discuss the various issues involved.

    Linkage: Because AMR is a recurring public-health crisis with direct links to governance, regulation, and science-tech, making it a favourite UPSC theme. The article shows rampant antibiotic misuse and OTC access driving India’s high resistance rates. This exactly reflects the PYQ’s focus on irrational use, weak monitoring, and stewardship gaps.